These findings suggest that measuring circulating levels of PGRN and EphA2 could facilitate early diagnosis and prognosis of coronary artery disease (CAD), particularly in assessing the severity of atherosclerosis and the risk of acute cardiovascular events. This evidence concerns the gene EPHA2 and coronary artery disorder.